Cited by 36Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisSystemic Sclerosis and Related DiseasesPulmonary Hypertension Research and Treatments

Multidisciplinary Evaluation in Patients with Lung Disease Associated with Connective Tissue Disease

Open access
Wells, Athol, Devaraj, Anand, Renzoni, Elizabetta A., Denton, Christopher P.·2019·Seminars in Respiratory and Critical Care Medicine

Abstract

Multidisciplinary diagnosis is now viewed as the diagnostic reference standard in interstitial lung disease (ILD). This process consists of the integration of the evidence base with clinical reasoning in the formulation of a diagnosis and requires input from clinicians, radiologists, and, in selected cases, histopathologists. In ILD associated with connective tissue disease (CTD-ILD), multidisciplinary evaluation is especially helpful when CTD is suspected but cannot be diagnosed using strict criteria. In this context, the integration of systemic clinical data, serologic information, and computed tomography and biopsy findings may allow CTD-ILD to be diagnosed. However, the value of multidisciplinary evaluation in CTD-ILD is not confined to diagnosis. The frequent coexistence of pulmonary processes other than ILD, including pulmonary vascular disease, extrapulmonic restriction, and airways disease, often has a major impact on symptoms and pulmonary function tests (PFTs). In this review, we highlight the value of multidisciplinary discussion (MDD) in reconciling clinical data, PFT, and imaging data in the accurate staging of disease severity, baseline prognostic evaluation, and the identification of progression of ILD. MDD also provides a means to combine the views of respiratory physicians and rheumatologists in formulating a treatment strategy. It is often possible to reach a robust view as to whether management should be driven by systemic disease, pulmonary disease, or both. When treatment needs to be introduced or modified for both systemic and pulmonary reasons, face-to-face discussion facilities the selection of therapeutic agents that are likely to be efficacious for both systemic and pulmonary diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1055/s-0039-1684020

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • When a patient's condition presents with ambiguous or overlapping symptoms, which can be difficult to distinguish from one another, this may lead to consultations with different specialists and referrals to arrive at a final diagnosis.

    “When a patient’s condition presents with ambiguous or overlapping symptoms, which can be difficult to distinguish from one another, this may lead to consultations with different specialists and referrals to arrive at a final diagnosis [272,273].”

    From Toward Safer Diagnoses: A SEIPS-Based Narrative Review of Diagnostic Errors (2026) · cites this paper as [272]

    The section “Diagnosis of CTD-ILD: The Role of MDD” says that uncertain diagnoses benefit from discussion among ILD physicians, CT radiologists, and rheumatologists. This supports the role of multiple specialists when a diagnosis is difficult, but the paper addresses CTD-associated lung disease specifically; it does not describe a general pattern of patients receiving referrals and separate consultations before a final diagnosis. Page numbers were not available in our copy. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 42

  1. Lynch DA, Sverzellati N, Travis WD, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med 2018;6(02):138-153 Review
  2. Tansey D, Wells AU, Colby TV, et al. Variations in histological patterns of interstitial pneumonia between connective tissue disorders and their relationship to prognosis. Histopathology 2004;44(06):585-596
  3. Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002;165(12): 1581-1586
  4. Park JH, Kim DS, Park IN, et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007;175(07):705-711
  5. Tsuchiya Y, Takayanagi N, Sugiura H, et al. Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur Respir J 2011;37(06):1411-1417
  6. Moua T, Zamora Martinez AC, Baqir M, Vassallo R, Limper AH, Ryu JH. Predictors of diagnosis and survival in idiopathic pulmonary fibrosis and connective tissue disease-related usual interstitial pneumonia. Respir Res 2014;15:154
  7. Kim EJ, Elicker BM, Maldonado F, et al. Usual interstitial pneu-monia in rheumatoid arthritis- associated interstitial lung dis-ease. Eur Respir J 2010;35(06):1322-1328
  8. Kelly CA, Saravanan V, Nisar M, et al; British Rheumatoid Inter-stitial Lung (BRILL) Network. Rheumatoid arthritis-related inter-stitial lung disease: associations, prognostic factors and physiological and radiological characteristics-a large multicentre UK study. Rheumatology (Oxford) 2014;53(09):1676-1682
  9. Yunt ZX, Chung JH, Hobbs S, et al. High resolution computed tomography pattern of usual interstitial pneumonia in rheuma-toid arthritis-associated interstitial lung disease: relationship to survival. Respir Med 2017;126:100-104
  10. Douglas WW, Tazelaar HD, Hartman TE, et al. Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med 2001;164(07):1182-1185
  11. Ito I, Nagai S, Kitaichi M, et al. Pulmonary manifestations of primary Sjogren's syndrome: a clinical, radiologic, and pathologic study. Am J Respir Crit Care Med 2005;171(06):632-638
  12. Castillo D, Walsh S, Hansell DM, et al; ERICE ILD working group. Validation of multidisciplinary diagnosis in IPF. Lancet Respir Med 2018;6(02):88-89
  13. Walsh SLF, Wells AU, Desai SR, et al. Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in dif-fuse parenchymal lung disease: a case-cohort study. Lancet Respir Med 2016;4(07):557-565
  14. Fischer A, Antoniou KM, Brown KK, et al; "ERS/ATS Task Force on Undifferentiated Forms of CTD-ILD". An official European Respiratory Society/American Thoracic Society research state-ment: interstitial pneumonia with autoimmune features. Eur Respir J 2015;46(04):976-987
  15. Luppi F, Wells AU. Interstitial pneumonitis with autoimmune features (IPAF): a work in progress. Eur Respir J 2016;47(06): 1622-1624
  16. Oldham JM, Adegunsoye A, Valenzi E, et al. Characterisation of patients with interstitial pneumonia with autoimmune features. Eur Respir J 2016;47(06):1767-1775
  17. Gibson GJ. Clinical Tests of Respiratory Function. London: Chap-pell and Hall; 1996:223-224
  18. Wells AU, Hansell DM, Rubens MB, Cailes JB, Black CM, du Bois RM. Functional impairment in lone cryptogenic fibrosing alveolitis and fibrosing alveolitis associated with systemic sclerosis: a comparison. Am J Respir Crit Care Med 1997;155 (05):1657-1664 21
  19. Cordier J-F. Organising pneumonia. Thorax 2000;55(04):318-328
  20. Burke CM, Glanville AR, Morris AJ, et al. Pulmonary function in advanced pulmonary hypertension. Thorax 1987;42(02): 131-135
  21. Goh NS, Hoyles RK, Denton CP, et al. Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol 2017;69(08):1670-1678
  22. Nathan SD, Shlobin OA, Ahmad S, Urbanek S, Barnett SD. Pul-monary hypertension and pulmonary function testing in idio-pathic pulmonary fibrosis. Chest 2007;131(03):657-663
  23. Steen VD, Graham G, Conte C, Owens G, Medsger TA Jr. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 1992;35(07):765-770
  24. Broderick A, Fuortes LJ, Merchant JA, Galvin JR, Schwartz DA. Pleural determinants of restrictive lung function and respiratory symptoms in an asbestos-exposed population. Chest 1992;101 (03):684-691
  25. Wright PH, Hanson A, Kreel L, Capel LH. Respiratory function changes after asbestos pleurisy. Thorax 1980;35(01):31-36
  26. Vincken WG, Elleker MG, Cosio MG. Flow-volume loop changes reflecting respiratory muscle weakness in chronic neuromuscular disorders. Am J Med 1987;83(04):673-680
  27. Braun NM, Arora NS, Rochester DF. Respiratory muscle and pulmonary function in polymyositis and other proximal myopa-thies. Thorax 1983;38(08):616-623
  28. Gibson GJ, Pride NB, Davis JN, Loh LC. Pulmonary mechanics in patients with respiratory muscle weakness. Am Rev Respir Dis 1977;115(03):389-395
  29. Gould GA, Redpath AT, Ryan M, et al. Lung CT density correlates with measurements of airflow limitation and the diffusing capa-city. Eur Respir J 1991;4(02):141-146
  30. Hansell DM, Rubens MB, Padley SPG, Wells AU. Obliterative bronchiolitis: individual CT signs of small airways disease and functional correlation. Radiology 1997;203(03):721-726
  31. Wells AU, King AD, Rubens MB, Cramer D, du Bois RM, Hansell DM. Lone cryptogenic fibrosing alveolitis: a functional-morphologic correlation based on extent of disease on thin-section computed tomography. Am J Respir Crit Care Med 1997;155(04):1367-1375
  32. Antoniou KM, Margaritopoulos GA, Goh NS, et al. Combined pulmonary fibrosis and emphysema in scleroderma-related lung disease has a major confounding effect on lung physiology and screening for pulmonary hypertension. Arthritis Rheumatol 2016;68(04):1004-1012
  33. Jacob J, Song JW, Yoon HY, et al. Prevalence and effects of emphysema in never-smokers with rheumatoid arthritis inter-stitial lung disease. EBioMedicine 2018;28:303-310
  34. Devaraj A, Wells AU, Meister MG, Corte TJ, Wort SJ, Hansell DM. Detection of pulmonary hypertension with multidetector CT and echocardiography alone and in combination. Radiology 2010;254 (02):609-616
  35. Shin S, King CS, Puri N, et al. Pulmonary artery size as a predictor of outcomes in idiopathic pulmonary fibrosis. Eur Respir J 2016; 47(05):1445-1451
  36. Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006;129(03):746-752
  37. Kawut SM, O'Shea MK, Bartels MN, Wilt JS, Sonett JR, Arcasoy SM. Exercise testing determines survival in patients with diffuse parenchymal lung disease evaluated for lung transplantation. Respir Med 2005;99(11):1431-1439
  38. Leuchte HH, Baumgartner RA, Nounou ME, et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med 2006;173(07):744-750
  39. Wells AU, Cullinan P, Hansell DM, et al. Fibrosing alveolitis associated with systemic sclerosis has a better prognosis than lone cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med 1994;149(06):1583-1590
  40. Marie I, Hachulla E, Chérin P, et al. Interstitial lung disease in polymyositis and dermatomyositis. Arthritis Rheum 2002;47 (06):614-622
  41. Tashkin DP, Elashoff R, Clements PJ, et al; Scleroderma Lung Study Research Group. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006;354(25): 2655-2666
  42. Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med 2012;156(10):684-691

Cited by

Sorted by citations

Authors
Wells, A., Devaraj, A., Renzoni, E. A., & Denton, C. P.
Affiliations
  • Royal Brompton Hospital (GB)
  • Interstitial Lung Disease Unit, Department of Imaging, Royal Brompton Hospital, London, United Kingdom
  • The Royal Free Hospital (GB)
Corresponding author
Wells, Athol
Venue
Seminars in Respiratory and Critical Care Medicine
Published
2019-04
Volume
40
Issue
02
Pages
184-193
ISSN
  • 1069-3424 (ISSN-L)
  • 1098-9048
OpenAlex
W2946893419
Cited by
36
References
2
Citations by year
2026: 5 · 2025: 3 · 2024: 3 · 2023: 6 · 2022: 10 · 2021: 3 · 2020: 2 · 2019: 4
FWCI
3.49
Type
journal article
Language
en
Open access
Locations
  • Seminars in Respiratory and Critical Care Medicine (publishedVersion)
  • PubMed (publishedVersion)
  • UCL Discovery (University College London) (submittedVersion)
Funders
Versus Arthritis (20719)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
  • Health Sciences › Medicine › Pathology and Forensic Medicine › Systemic Sclerosis and Related Diseases
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
Keywords
connective tissue disease-associated interstitial lung disease, multidisciplinary assessment, multidisciplinary discussion, disease staging, prognosis, disease progression, pulmonary vascular disease, airway disease, pulmonary function tests, computed tomography, lung biopsy, treatment options
MeSH terms
Connective Tissue Diseases, Humans, Prognosis, Lung Diseases, Interstitial, Disease Progression, Interdisciplinary Communication

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review